TherapeuticsMD, Inc. operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen. The company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaMedMD and BocaGreenMD brands. It markets its products primarily through a direct national sales force to health care providers in the OB/GYN market space. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TXMD
CUSIPN/A
Phone561-961-1900
Debt
Debt-to-Equity RatioN/A
Current Ratio7.61
Quick Ratio7.51
Price-To-Earnings
Trailing P/E Ratio-18.95
Forward P/E Ratio-13.23
P/E GrowthN/A
Sales & Book Value
Annual Sales$16.78 million
Price / Sales90.48
Cash FlowN/A
Price / CashN/A
Book Value$0.60 per share
Price / Book11.68
Profitability
EPS (Most Recent Fiscal Year)($0.37)
Net Income$-76,920,000.00
Net Margins-483.98%
Return on Equity-66.77%
Return on Assets-60.12%
Miscellaneous
Employees173
Outstanding Shares216,580,000
TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions
What is TherapeuticsMD's stock symbol?
TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."
How were TherapeuticsMD's earnings last quarter?
TherapeuticsMD Inc (NASDAQ:TXMD) issued its quarterly earnings results on Thursday, May, 3rd. The company reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.01. The business earned $3.77 million during the quarter, compared to analyst estimates of $4.18 million. TherapeuticsMD had a negative return on equity of 66.77% and a negative net margin of 483.98%. TherapeuticsMD's quarterly revenue was down 5.4% compared to the same quarter last year. During the same quarter last year, the company posted ($0.11) EPS. View TherapeuticsMD's Earnings History.
What price target have analysts set for TXMD?
10 brokers have issued 12 month target prices for TherapeuticsMD's stock. Their predictions range from $6.00 to $28.00. On average, they expect TherapeuticsMD's share price to reach $14.6250 in the next twelve months. View Analyst Ratings for TherapeuticsMD.
Are investors shorting TherapeuticsMD?
TherapeuticsMD saw a increase in short interest during the month of May. As of May 31st, there was short interest totalling 59,347,738 shares, an increase of 7.7% from the May 15th total of 55,097,382 shares. Based on an average daily trading volume, of 5,051,744 shares, the days-to-cover ratio is currently 11.7 days. Approximately 34.2% of the company's stock are sold short. View TherapeuticsMD's Current Options Chain.
Who are some of TherapeuticsMD's key competitors?
Some companies that are related to TherapeuticsMD include Dr.Reddy's Laboratories (RDY), Catalent (CTLT), Agios Pharmaceuticals (AGIO), Ionis Pharmaceuticals (IONS), Loxo Oncology (LOXO), FibroGen (FGEN), United Therapeutics (UTHR), GALAPAGOS NV/S (GLPG), Taro Pharmaceutical Industries (TARO), Madrigal Pharmaceuticals (MDGL), Ultragenyx Pharmaceutical (RARE), Ligand Pharmaceuticals (LGND), GW Pharmaceuticals (GWPH), HUTCHISON CHINA/S (HCM) and Array Biopharma (ARRY).
Who are TherapeuticsMD's key executives?
TherapeuticsMD's management team includes the folowing people:
- Mr. Robert G. Finizio, Co-Founder, CEO & Director (Age 47)
- Mr. John C. K. Milligan IV, Pres, Sec. & Director (Age 56)
- Dr. Brian A. Bernick, Co-Founder, Chief Clinical Officer & Director (Age 50)
- Mr. Daniel Alan Cartwright, CFO, Treasurer & Principal Accounting Officer (Age 60)
- Mr. Mitchell L. Krassan, Chief Strategy Officer and Exec. VP (Age 52)
Has TherapeuticsMD been receiving favorable news coverage?
News headlines about TXMD stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. TherapeuticsMD earned a news sentiment score of 0.09 on Accern's scale. They also assigned media headlines about the company an impact score of 46.62 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.
Who are TherapeuticsMD's major shareholders?
TherapeuticsMD's stock is owned by many different of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (9.08%), BlackRock Inc. (6.43%), Franklin Resources Inc. (4.88%), Stifel Financial Corp (0.86%), First Eagle Investment Management LLC (0.81%) and OppenheimerFunds Inc. (0.76%). View Institutional Ownership Trends for TherapeuticsMD.
Which major investors are selling TherapeuticsMD stock?
TXMD stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Franklin Resources Inc., Guggenheim Capital LLC, Teacher Retirement System of Texas, Claraphi Advisory Network LLC and California State Teachers Retirement System. View Insider Buying and Selling for TherapeuticsMD.
Which major investors are buying TherapeuticsMD stock?
TXMD stock was purchased by a variety of institutional investors in the last quarter, including First Eagle Investment Management LLC, DekaBank Deutsche Girozentrale, GSA Capital Partners LLP, Trellus Management Company LLC, Iridian Asset Management LLC CT, Cubist Systematic Strategies LLC, Schwab Charles Investment Management Inc. and Barclays PLC. View Insider Buying and Selling for TherapeuticsMD.
How do I buy shares of TherapeuticsMD?
Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TherapeuticsMD's stock price today?
One share of TXMD stock can currently be purchased for approximately $7.01.
How big of a company is TherapeuticsMD?
TherapeuticsMD has a market capitalization of $1.58 billion and generates $16.78 million in revenue each year. The company earns $-76,920,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. TherapeuticsMD employs 173 workers across the globe.
How can I contact TherapeuticsMD?
TherapeuticsMD's mailing address is 6800 BROKEN SOUND PARKWAY NW, BOCA RATON FL, 33487. The company can be reached via phone at 561-961-1900 or via email at [email protected]
MarketBeat Community Rating for TherapeuticsMD (TXMD)
MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote "Outperform" if you believe TXMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TXMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
